Radiologists imaging and biopsying prostate cancers with notable success

Dave Pearson | | Health Imaging | Artificial Intelligence

A radiology team at Virginia Commonwealth University Medical Center is using advanced multiparametric MRI to diagnose difficult prostate cancers with upwards of 90 percent accuracy—and then perform targeted biopsies guided by MRI and ultrasound.

“At most places, there will be a radiologist reading the MR image and a clinician performing the biopsy. The person reading the image and person putting in the needle is different,” explains radiologist Jinxing Yu, MD, the institution’s director of oncologic and prostate imaging. 

“We do both. That’s one of our strengths.”

Get the rest from the university’s news office: 

Increasing the odds of prostate cancer detection

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.